The introduction of multiparametric magnetic resonance imaging (mpMRI) has enhanced risk stratification for men at risk of prostate cancer, beyond the traditional standard of serum prostate-specific antigen (PSA) and systematic transrectal ultrasound (TRUS)-guided prostate biopsy [1], [2], [3], [4]. This evidence concerns the gene KLK3 and Familial prostate cancer.